Filing Details
- Accession Number:
- 0000919574-20-006829
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-11-12 18:23:35
- Reporting Period:
- 2020-11-10
- Accepted Time:
- 2020-11-12 18:23:35
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1371217 | Reshape Lifesciences Inc. | RSLS | Electromedical & Electrotherapeutic Apparatus (3845) | 481293684 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1601086 | Armistice Capital, Llc | 510 Madison Avenue, 7Th Floor New York NY 10022 | No | No | Yes | No | |
| 1633584 | Ltd. Fund Master Capital Armistice | C/O Dms Corporate Services Ltd. 20 Genesis Close, P.o. Box 314 Grand Cayman E9 KY1-1104 | No | No | Yes | No | |
| 1706140 | Steven Boyd | C/O Armistice Capital, Llc 510 Madison Avenue, 7Th Floor New York NY 10022 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-11-10 | 2,400 | $3.58 | 5,322,900 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2020-11-10 | 0 | $0.00 | 5,322,900 | No | 4 | P | Indirect | See Footnote |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct | |
| No | 4 | P | Indirect | See Footnote |
Footnotes
- The reported securities are directly owned by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital. Armistice Capital and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- This constitutes the weighted average purchase price. The prices range from $3.54 to $3.78. The Reporting Persons will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price
Billionaire Hedge Funds
